Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the efficacy and safety of lixisenatide (20 μg once daily, administered before the morning or evening meal) as add-on therapy in patients with type 2 diabetes insufficiently controlled with metformin alone. RESEARCH DESIGN AND METHODS: This was a 24-week, randomized, double-blind, placebo-controlled study in 680 patients with inadequately controlled type 2 diabetes (HbA1c 7–10% [53−86 mmol/mol]). Patients were randomized to lixisenatide morning (n = 255), lixisenatide evening (n = 255), placebo morning (n = 85), or placebo evening (n = 85) injections. RESULTS: Lixisenatide morning injection significantly reduced mean HbA1c versus combined placebo (mean change −0.9% [9.8 mmol/mol] vs. −0.4% [4.4 mmol/mol]; least squares [LS] mean difference vs. placebo −0.5% [5.5 mmol/mol], P < 0.0001). HbA1c was significantly reduced by lixisenatide evening injection (mean change –0.8% [8.7 mmol/mol] vs. –0.4% [4.4 mmol/mol]; LS mean difference –0.4% [4.4 mmol/mol], P < 0.0001). Lixisenatide morning injection significantly reduced 2-h postprandial glucose versus morning placebo (mean change −5.9 vs. −1.4 mmol/L; LS mean difference −4.5 mmol/L, P < 0.0001). LS mean difference in fasting plasma glucose was significant in both morning (–0.9 mmol/L, P < 0.0001) and evening (–0.6 mmol/L, P = 0.0046) groups versus placebo. Mean body weight decreased to a similar extent in all groups. Rates of adverse events were 69.4% in both lixisenatide groups and 60.0% in the placebo group. Rates for nausea and vomiting were 22.7 and 9.4% for lixisenatide morning and 21.2 and 13.3% for lixisenatide evening versus 7.6 and 2.9% for placebo, respectively. Symptomatic hypoglycemia occurred in 6, 13, and 1 patient for lixisenatide morning, evening, and placebo, respectively, with no severe episodes. CONCLUSIONS: In patients with type 2 diabetes inadequately controlled on metformin, lixisenatide 20 μg once daily administered in the morning or evening significantly improved glycemic control, with a pronounced postprandial effect, and was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 LS mean change in postprandial glucose (A) and glucose excursion (B) from baseline to week 24 (last observation carried forward [LOCF]) with lixisenatide morning and placebo morning once-daily regimens. Data are mean values for the mITT population. Error bars represent the standard error. Glucose excursion calculated as 2-h PPG minus plasma glucose 30 min prior to the meal before study drug administration.](https://figures.cochat.ai/paper-figures/6c4743ce03ec4ab4812ca9679c66de5c/efficacy-and-safety-of-lixisenatide-once-daily-morning-or-evening-injections-in-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Once daily lixisenatide, structurally similar to exenatide and administered by subcutaneous injection, was later approved and found to reduce HbA1c by 0.8–0.9%.14”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“7 mmol/mol [66 to 57 mmol/mol]) using the highest dose of 10 mg twice daily (10).”
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Pratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 586
Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261
Seino, Y., Min, K. W., Niemoeller, E., Takami, A., & on behalf of the EFC10887 GETGOAL‐L Asia Study Investigators (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01618.x · Cited by 255
Rosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care · doi:10.2337/dc12-2709 · Cited by 253
Self-citationEfficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1935 · Cited by 218
Self-citation
Cited by
Items 101–181 of 181
Chen, J., Zhang, Q., Wu, Q., Zhang, X., Xiang, Z., Zhu, S., Dai, T., & Si, Y.-X. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70151 · Cited by 17
Hanefeld, M., Berria, R., Lin, J., Aronson, R., Darmon, P., Evans, M., & Gaal, L. V. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0146-4 · Cited by 18
“peptide receptor agonist (GLP-1 RA) for the treatment of T2DM, has a favorable effect on PPG excursions with a good tolerability profile [16–20], suggesting that lixisenatide is a suitable treatment for the pathophysiology of T2DM in”
BackgroundMethodSelf-citationJia, S., Wang, Z., Han, R., Zhang, Z., Li, Y., Qin, X., Zhao, M., Xiang, R., & Yang, J. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01542-4 · Cited by 18
Injectable Coformulations in Diabetology
Kalra, S., & Gupta, Y. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0106-2 · Cited by 17
“GetGoal-M [25]: double-blind placebo-controlled study where the patients were randomized to receive injections of lixisenatide in the morning, lixisenatide in the evening, placebo in the morning, or placebo in the evening (680) 24 From a baseline HbA1C of 8.”
Farngren, J., Persson, M., & Åhrén, B. (2015) · Diabetes Care · doi:10.2337/dc15-1274 · Cited by 18
“It improves glycemia with low risk for hypoglycemia both in monotherapy, in association with metformin and in combination with insulin (20-23).”
BackgroundEfficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus
Leiter, L. A., & Nauck, M. A. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-103969 · Cited by 16
Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes
Yabe, D., & Seino, Y. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.949672 · Cited by 16
“9% over 24 weeks [33–36].”
Raccah, D., Gourdy, P., Sagnard, L., & Ceriello, A. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2548 · Cited by 14
“GetGoal-M (an investigation of morning versus evening dosing with lixisenatide) [3] was the only study included in this meta-analysis where the increased occurrence of symptomatic hypoglycaemia approached significance, with the 95% CI just crossing the line of unity.”
ResultLixisenatide as add-on therapy to basal insulin
Evans, M., Butler, E. L., & Brown, D. X. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s45108 · Cited by 17
Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials
Blonde, L., Chava, P., DEX, T. A., Lin, J., Nikonova, E. V., & Goldenberg, R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12815 · Cited by 15
“0001 Patients experiencing ≥1 symptomatic hypoglycaemic event(3), n (%) 94 (5) 28 (3) .”
Pérez, M. B., Hsia, D. S., Sloan, L. A., Nell, H., Mungur, O., Hovsepian, L., Schmider, W., Spranger, R., Yang, N., & Niemoeller, E. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13343 · Cited by 14
“Body weight increase was more pronounced with placebo versus lixisenatide, which reflected the trend for the positive effects of lixisenatide on body weight observed in the adult lixisenatide development program.(22,23,25) Since the short duration of this study may have limited the impact on body weight change, data g…”
ResultMoore, M. C., Werner, U., Smith, M. S., Farmer, T. D., & Cherrington, A. D. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00354.2013 · Cited by 12
Onishi, Y., Niemoeller, E., Ikeda, Y., Takagi, H., Yabe, D., & Seino, Y. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12275 · Cited by 13
Sheng, L., Deng, M., Li, X., Wan, H. Y., Lei, C., Prabahar, K., Hernández‐Wolters, B., & Kord‐Varkaneh, H. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111617 · Cited by 13
The role of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
Onge, E. S., Miller, S. A., Clements, E. A., Celauro, L., & Barnes, K. (2017) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2017-0015 · Cited by 13
“Lixisenatide Lixisenatide, the newest GLP-1 agonist to be approved in the US, has been studied in patients on metformin monotherapy in two studies.[35,36] In the first study, 680 patients were randomized to receive lixisenatide 20 mcg in the evening, lixisenatide 20 mcg in the morning, placebo in the evening, or place…”
BackgroundOsumili, B., Sapin, H., Yang, Z., Ranta, K., Paik, J. S., & Blüher, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01728-5 · Cited by 16
Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy
Davidson, J. A. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1096743 · Cited by 12
Men, P., Qu, S., Song, Z., Liu, Y., Li, C., & Zhai, S. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00857-3 · Cited by 12
Lin, C., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · BMC Medicine · doi:10.1186/s12916-020-01787-4 · Cited by 12
A drug and disease model for lixisenatide, a GLP‐1 receptor agonist in type 2 diabetes
Wilkins, J. J., Dubar, M., Sébastien, B., & Laveille, C. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.192 · Cited by 12
Lixisenatide – A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes
Vidal, J. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2013.09.02.76 · Cited by 15
Handelsman, Y., Muskiet, M. H. A., & Meneilly, G. S. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01126-x · Cited by 12
“The GLP-1 RA, lixisenatide, has been studied in over 40 clinical trials and has shown significant beneficial effects on HbA1c reduction and 2-h PPG in numerous settings, including when used as monotherapy (GetGoal-Mono) [56], add-on to oral therapy (GetGoal-S [67], GetGoalF-1 [68], GetGoal-X (vs. exenatide) [69], GetG…”
Fisher, M. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12380 · Cited by 11
Haluzík, M., Seufert, J., Guja, C., Bonnemaire, M., Bigot, G., Tournay, M., Kis, J. T., & Freemantle, N. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01375-8 · Cited by 11
“In line with the reported effectiveness and safety of iGlarLixi at all administration times in the current analysis, two 24-week RCTs, evaluating lixisenatide injected once daily at 20 lg in individuals with T2DM inadequately controlled on metformin, demonstrated that the efficacy and safety of lixisenatide do not var…”
Yuan, S., & Wu, Y. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1201818 · Cited by 11
Lixisenatide: A New Option for Managing Type 2 Diabetes
Newsome, J. S. (2017) · Journal of Pharmacy Technology · doi:10.1177/8755122517711958 · Cited by 11
Drug-induced regeneration of pancreatic beta cells: An approach to cellular therapeutic targets
Parsi, P., Saharkhiz, S., Farani, M. R., Bakhtiyari, S., & Alipourfard, I. (2025) · Cell Regeneration · doi:10.1186/s13619-025-00255-9 · Cited by 9
“Nevertheless, lixisena-tide is currently available in the United States alongside insulin glargine (iGlarLixi ® ); it is no longer sold alone as of 2023 (Anderson and Trujillo 2016; Ahrén et al. 2013).”
Ah, B., & Orme, M. E. (2014) · Internal Medicine Open Access · doi:10.4172/2165-8048.s6-006 · Cited by 9
“In total,19 studies were included in the base case analysis at 24-weeks ± 6 weeks [7,23,25-41] (Table S2) and a further 4 were eligible for the sensitivity analysis due to timeframe (± 8 weeks) and quality issues (Table S4).”
BackgroundResultPetrova, L., Andreevska, K., Parvova, I., & Petkova, V. B. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e132148 · Cited by 9
A systematic review of the safety of incretin-based therapies in type 2 diabetes
Evans, M., Bain, S. C., & Vora, J. P. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1057502 · Cited by 8
Bergenstal, R. M., Strock, E. S., Mazze, R. S., Powers, M. A., Monk, A. M., Richter, S. A., Souhami, E., & Åhrén, B. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2879 · Cited by 8
“However, one trial included morning or evening dosing.(9) This trial found that both morning and evening administration of lixisenatide significantly lowered mean HbA1c compared with placebo, and both regimens were generally well tolerated.”
BackgroundWali, A. F., Rangraze, I. R., Khan, S. S., Mufti, U., El‐Tanani, M., & Rizzo, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1736380 · Cited by 7
Seino, Y., Terauchi, Y., Wang, X., Watanabe, D., Niemoeller, E., & the study investigators (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12646 · Cited by 7
Terauchi, Y., Usami, M., & Inoue, T. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02121-5 · Cited by 7
Kamalinia, S., Josse, R. G., Donio, P. J., Leduc, L., Shah, B. R., & Tobe, S. W. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.100 · Cited by 7
Shepard, B. D., & ECELBARGER, C. A. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.06.005 · Cited by 7
Ho, M. J., Liew, C. F., Tan, N. A. M. R., Morita, A., & Oon, H. H. B. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2665732 · Cited by 7
Baker, D. E., & Levien, T. L. (2017) · Hospital Pharmacy · doi:10.1310/hpj5201-65 · Cited by 6
Broglio, F., Mannucci, E., Napoli, R., Nicolucci, A., Purrello, F., Nikonova, E., Stager, W., & Trevisan, R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12810 · Cited by 6
“This increase is probably explained by the fact that the lixisenatide evening injection arm showed an unexpected slightly higher incidence of symptomatic hypoglycaemia events with respect to the morning injection arm, although none was severe in intensity.(16) Also, a recent meta-analysis of the efficacy and safety of…”
ResultHtike, Z., Zaccardi, F., Chatterjee, S., Khunti, K., & Davies, M. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.091 · Cited by 6
Prise en charge du diabète de type 2 : anciens ou nouveaux médicaments, comment choisir ?
Halimi, S. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.04.002 · Cited by 6
“[25] Ahrén B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R.”
Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus
Hanefeld, M., Raccah, D., & Monnier, L. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1251579 · Cited by 5
“In a meta-analysis of five trials from the GetGoal clinical trial program (GetGoal-S, GetGoal-P, GetGoal-M, GetGoal-M-Asia [NCT01169779] and GetGoal-F1 [NCT00763451]), the efficacy and safety of lixisenatide as add-on to OADs in 501 patients ≥65 years of age was assessed.”
Yamada, Y., Senda, M., Naito, Y., Tamura, M., Watanabe, D., Shuto, Y., & Urita, Y. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12945 · Cited by 6
WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
Lovshin, J. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.02.003 · Cited by 3
RetractedÅhrén, B., Galstyan, G. R., Gautier, J., Giorgino, F., Peralta, F. G., Krebs, M., Nikonova, E., Stager, W., & Vargas‐Uricoechea, H. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0179-6 · Cited by 5
“As reported previously [10, 11], GetGoal-M and GetGoal-S included patients who had T2DM for C1 year and HbA1c levels of 7–10%.”
MethodGrandy, S., & Shaunik, A. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000643 · Cited by 6
“In a 24-week, randomized, placebo-controlled trial (N=680), treatment with lixisenatide 20 μg once daily (either in the morning or evening) significantly improved β-cell function compared with placebo [51].”
BackgroundLauri, G., Arcidiacono, P. G., Facciorusso, A., Capurso, G., & Tacelli, M. (2026) · Pancreatology · doi:10.1016/j.pan.2026.04.005 · Cited by 4
Aronson, R. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.842465 · Cited by 5
Self-citationSchubert, A., Buchholt, A. T., Khoury, A. C. E., Kamal, A., & Taieb, V. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1310091 · Cited by 5
Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?
Kühn, A., Park, J., Ghazi, A., & Aroda, V. R. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0832-3 · Cited by 4
Seino, Y., Stjepanovic, A., Takami, A., Takagi, H., & the study investigators (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12686 · Cited by 4
“Discontinued treatment n = 3 Adverse event (3) Lack of efficacy (0) Poor compliance (0) Other reasons (0) Discontinued treatment n = 12 Adverse event (10) Lack of efficacy (1) Poor compliance (0) Other reasons (1) Discontinued treatment n = 8 Adverse event (8) Lack of efficacy (0) Poor compliance (0) Other reasons (0)…”
BackgroundFactors Associated with Medicine Timing Effects: A Meta-analysisPreprint
Ruben, M. D., Francey, L. J., Wu, G., Smith, D. F., FitzGerald, G. A., Hughey, J., & Hogenesch, J. B. (2021) · medRxiv · doi:10.1101/2021.10.24.21265348 · Cited by 5
Lixisenatide: clinical profile and available evidence
Dicembrini, I., Bigiarini, M., & Mannucci, E. (2013) · Diabetes Management · doi:10.2217/dmt.13.64 · Cited by 3
Number-Based Approach to Insulin Taxonomy
Kalra, S., & Gupta, Y. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0129-8 · Cited by 3
Harreiter, J., Kosi‐Trebotic, L., Lukas, A., Wolf, P. S., Winhofer, Y., Luger, A., Kautzky‐Willer, A., & Krebs, M. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0249-4 · Cited by 3
Wei, Z., Wang, M., Zhang, H., Wang, Z., Wang, G.-N., Wei, F., Zhang, Y., Xu, X., & Zhang, Y. (2018) · Medicine · doi:10.1097/md.0000000000013710 · Cited by 3
Bai, S., Lin, C., Jiao, R., Cai, X., Hu, S., Lv, F., Yang, W., Zhu, X., & Ji, L. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.01.008 · Cited by 2
Chau, H. C., Liu, J. Y. H., & Rudd, J. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-95961-4 · Cited by 2
“22 , showed prediction values of 0.80 and 0.78 for nausea and vomiting, respectively.”
InfluentialLixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus
Forst, T. M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1206079 · Cited by 2
“Lixisenatide also reduces body weight or is weight neutral [10,11].”
BackgroundTemelkova, N., Vladeva, S. V., Delchev, A., Ivanova, K., Gerasimova-Zheleva, Y., Kuneva, T., Pehlivanova, V., & Popivanov, P. R. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0603-9 · Cited by 2
Ruan, Z., Chen, X., Song, M., Jia, R., Luo, H., Ung, C. O. L., & Hu, H. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s483065 · Cited by 3
Zhou, L., Wu, P., Xu, Y., & Xie, B. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02697-2 · Cited by 2
Semaglutide and Exercise Synergy in Obesity: Preserving Muscle Mass and Uncovering Organ Crosstalk
Inia, J. A., Droog, S., Snabel, J. M., Menke, A. L., Caspers, M. P. M., de Jong, J. C. B. C., Jukema, J. W., Princen, H. M. G., & van den Hoek, A. M. (2026) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.1060 · Cited by 1
Ortiz-Seller, A., Real, J. T., Morcillo, E. J., & Ortiz, J. L. (2026) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2026.08.007 · Cited by 1
Importance of the postprandial glycemic control in the patient with Type 2 Diabetes Mellitus
Benítez, A., Benítez, G., Barriocanal, L. A., Bueno, E., Caballero, A., Cañete, F., Jiménez, J., Logwin, S., Menoni, C., Palacios, M., et al. (2016) · Anales de la Facultad de Ciencias Médicas (Asunción) · doi:10.18004/anales/2015.048(01)83-100 · Cited by 4
Adjunctive Therapy, Including Pharmacotherapy
Al-Bazz, D. Y., & Wilding, J. P. H. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch21 · Cited by 1
Лечение аналогами глюкагоноподобного пептида-1 — прорыв в терапии сахарного диабета 2-го типа
Orlenko, V. L., & Kp, Z. (2014) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.4.60.2014.76690 · Cited by 3
New pharmacological approaches to diabetes management
Eyadeh, A. A., & Jennings, P. E. (2015) · Practice Nursing · doi:10.12968/pnur.2015.26.3.140
Lixisenatide: a guide to its use as add-on therapy in type 2 diabetes mellitus
Lyseng-Williamson, K. A., & Scott, L. J. (2013) · Drugs & Therapy Perspectives · doi:10.1007/s40267-013-0059-3
“Although add-on therapy with lixisenatide was associated with modest bodyweight changes in the other placebo-controlled GetGoal trials [13, 14, 16, 18], the LSM reductions in bodyweight at week 24 were not significantly different than those with placebo.”
BackgroundPharmacologic Approach to Type 2 Diabetes in Obese Patients
Litwak, L., Musso, C., & Fuentes, S. (2014) · Springer eBooks · doi:10.1007/978-3-319-13126-9_10
Lixisenatide: A New Glucagon-Like Peptide-1 Agonist
Ho, C. W. (2013) · Journal of Developing Drugs · doi:10.4172/2329-6631.1000e134
“Currently, the use of lixisenatide has been evaluated in multiple phase 3 clinical trials [15-23].”
BackgroundLixisenatide: a once-daily glucagon-like peptide-1 receptor agonist
Chudiwal, T. B., & Sharma, I. (2016) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20164085
Diabetic Pharmacotherapies in Kidney Disease
Chon, D. A., Oxman, R. T., MULLUR, R. S., & Weinreb, J. E. (2019) · Springer eBooks · doi:10.1007/978-3-319-97765-2_5
Handelsman, Y., Muskiet, M. H. A., & Meneilly, G. S. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01185-0
Chu, L., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · Figshare · doi:10.6084/m9.figshare.13240350
Khawandanah, D. O., Alyamani, F. F., Almutairi, B. R., Almutairi, B. A., Alharbi, R. M., Alghanmi, S., Alsouri, M. T., & ALMUTAIRI, A. R. (2025) · Saudi Journal of Clinical Pharmacy · doi:10.4103/sjcp.sjcp_22_25 · Cited by 1
Optimizing GLP-1 Receptor Agonist Use: Mechanisms, Clinical Applications, and Safety Profiles
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8391-3
Amani‐Beni, R., Darouei, B., Maleki, S., Sadri, H., Seifnezhad, A., Eshraghi, R., Bahrami, A., Ebrahimi, P., Shahid, F., Upadhyaya, S., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02271-4
Petrova, L., Andreevska, K., Parvova, I., & Petkova, V. (2024) · doi:10.3897/pharmacia.71.e132148.figure1
Hu, W., Song, R., Cheng, R., Liu, C., Guo, R., Tang, W., Zhang, J., Zhao, Q., Li, X., & Liu, J. (2022) · doi:10.3389/fendo.2022.927859.s001
Metadata
- Authors
- Ahrén, B., Leguizamo Dimas, A., Miossec, P., Saubadu, S., & Aronson, R.
- Affiliations
- Lund University, Lund, Sweden
- Centro de Investigación Clínica del Pacifico, Acapulco, Mexico
- Sanofi (France) (FR)
- LMC Diabetes & Endocrinology (Canada) (CA)
- ORCID
- Aronson, Ronnie
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-08-13
- Volume
- 36
- Issue
- 9
- Pages
- 2543-2550
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3747937
- OpenAlex
- W2154433510
- Cited by
- 172
- References
- 27
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 5 · 2023: 9 · 2022: 4 · 2021: 4 · 2020: 5 · 2019: 8 · 2018: 9 · 2017: 23 · 2016: 24 · 2015: 17 · 2014: 29 · 2013: 17
- FWCI
- 22.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- lixisenatide, type 2 diabetes, metformin add-on therapy, inadequate glycemic control, HbA1c reduction, postprandial blood glucose, fasting blood glucose, body weight, nausea and vomiting, GLP-1 receptor agonists, injection timing, GIP/GLP-1 receptor agonist
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.